Trial Profile
An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Registrational; Therapeutic Use
- Acronyms PRISM
- Sponsors LFB Biotechnologies
- 01 Nov 2022 Results of post-hoc analysis assessing the variability using multiple outcome measures, published in the Muscle and Nerve.
- 27 Nov 2017 Status changed from recruiting to completed.
- 25 Oct 2017 The trial has been completed in Spain.